Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
IMUX Immunic
- 1.120
- -0.030-2.61%
Close May 5 16:00 ET
- 1.111
- -0.009-0.82%
Post 20:01 ET
107.32MMarket Cap-1.12P/E (TTM)
1.200High1.120Low1.12MVolume1.150Open1.150Pre Close1.29MTurnover1.59%Turnover RatioLossP/E (Static)95.82MShares2.11052wk High5.83P/B78.71MFloat Cap0.83252wk Low--Dividend TTM70.27MShs Float28.990Historical High--Div YieldTTM6.96%Amplitude0.832Historical Low1.153Avg Price1Lot Size
About Immunic Company
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
Company Profile
SymbolIMUX
Company NameImmunic
Listing DateApr 17, 2014
Issue Price12.00
Founded2003
CEODr. Daniel Vitt, PhD
MarketNASDAQ
Employees77
Fiscal Year Ends12-31
Address1200 Avenue of the Americas,Suite 200
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036
Phone1-332-255-9818
Websitehttp://imux.com
Company Executives
- Name
- Position
- Salary
- Dr. Daniel Vitt, PhD
- Director and Chief Executive Officer
- 2.94M
- Werner Gladdines
- Chief Development Officer
- --
- Patrick Walsh
- Chief Business Officer
- --
- Jason Tardio, M.B.A.
- Chief Operating Officer and President
- 1.03M
- Glenn Whaley
- Chief Financial Officer and Principal Accounting Officer
- 1.17M
- Dr. Hella Kohlhof
- Chief Scientific Officer
- --
- Dr. Andreas Muehler
- Chief Medical Officer
- 1.37M
- Dr. Duane D. Nash, M.D.
- Executive Chairman of the Board
- 1.21M
- Simona Skerjanec, M.B.A.
- Director
- 193.14K
- Tamar D. Howson
- Independent Director
- 176.74K
- Monika Maria Tornsen
- Independent Director
- 158.39K
- Richard Alan Rudick
- Independent Director
- 148.90K
- Barclay A. Phillips
- Lead Independent Director
- 196.00K
- Dr. Jorg Neermann, PhD
- Independent Director
- 185.28K
- Inderpal Singh
- General Counsel
- --
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
